Literature DB >> 30446462

Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model.

Mohamed D Ray-Zack1, Yong Shan1, Hemalkumar B Mehta2, Xiaoying Yu3, Ashish M Kamat4, Stephen B Williams5.   

Abstract

OBJECTIVE: Length of hospital stay for patients following radical cystectomy is an important determinant for improved quality of care. We sought to develop and validate a predictive model for length of hospital stay following radical cystectomy.
METHODS: Patients aged 66 to 90 years diagnosed with clinical stage T2-4a muscle-invasive bladder cancer who underwent radical cystectomy were included from January 1, 2002 through December 31, 2011 using the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Linear regression analyses were used to develop and validate a predictive model for length of hospital stay.
RESULTS: A total of 2,448 patients met inclusion criteria. After random assignment, 1,224 patients were included in the discovery cohort and 1,224 patients included in the validation cohort. The cohorts were well balanced with no significant difference in any of the preoperative variables. A best model was developed using marital status, Surveillance, Epidemiology, and End Results (SEER) region, clinical stage, Charlson comorbidity index, logarithm of hospital cystectomy volume, and use of neoadjuvant chemotherapy in a backward selection to predict the length of stay. There was robust internal validation (sum square error (SSE): 258.1 vs. predicted sum of squares (PRESS): 264.0 at SLS = 0.10), consistent with the external validation (average square error (ASE): discovery (0.248) vs. validation (0.258)) cohort. The strength of the model in predicting length of stay for the entire cohort was (R2 = 0.048).
CONCLUSION: In this large population-based study, we developed and validated a model to predict length of hospital stay following radical cystectomy. Identification of at-risk patients for prolonged hospital stay may aid in targeted interventions to reduce length of stay, improve quality of care, and decrease healthcare costs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Hospital stay; Model; Prediction; Radical cystectomy; SEER

Mesh:

Year:  2018        PMID: 30446462      PMCID: PMC7682754          DOI: 10.1016/j.urolonc.2018.10.024

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  17 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project.

Authors:  Badrinath R Konety; Vibhu Dhawan; Veerasathpurush Allareddy; Sue A Joslyn
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

3.  Marital status: a gender-independent risk factor for poorer survival after radical cystectomy.

Authors:  Jesse D Sammon; Monica Morgan; Orchidee Djahangirian; Quoc-Dien Trinh; Maxine Sun; Khurshid R Ghani; Wooju Jeong; Jay Jhaveri; Michael Ehlert; Jan Schmitges; Marco Bianchi; Shahrokh F Shariat; Paul Perrotte; Craig G Rogers; James O Peabody; Mani Menon; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2012-03-27       Impact factor: 5.588

4.  Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.

Authors:  Stephen B Williams; Jinhai Huo; Karim Chamie; Jim C Hu; Sharon H Giordano; Karen E Hoffman; Colin P N Dinney; Ashish M Kamat; Ya-Chen Tina Shih
Journal:  Eur Urol Focus       Date:  2016-05-13

5.  Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.

Authors:  Stephen B Williams; Jinhai Huo; Christopher D Kosarek; Karim Chamie; Selwyn O Rogers; Michele A Williams; Sharon H Giordano; Simon P Kim; Ashish M Kamat
Journal:  Cancer Causes Control       Date:  2017-05-05       Impact factor: 2.506

6.  Participation of patients 65 years of age or older in cancer clinical trials.

Authors:  Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.

Authors:  David B Cahn; Elizabeth A Handorf; Eric M Ghiraldi; Benjamin T Ristau; Daniel M Geynisman; Thomas M Churilla; Eric M Horwitz; Mark L Sobczak; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Alexander Kutikov; Robert G Uzzo; Marc C Smaldone
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

8.  Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies.

Authors:  Hannah K Weir; Christopher J Johnson; Angela B Mariotto; Donna Turner; Reda J Wilson; Diane Nishri; Kevin C Ward
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

9.  Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index.

Authors:  Xiaosong Meng; Benjamin Press; Audrey Renson; James S Wysock; Samir S Taneja; William C Huang; Marc A Bjurlin
Journal:  Clin Genitourin Cancer       Date:  2018-02-26       Impact factor: 2.872

10.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.